PCAS

Earnings Release • Apr 23, 2013

PCAS: QUARTERLY FINANCIAL INFORMATION

(as of 31 March, 2013)

Longjumeau, April 23, 2013

Net sales

(in thousands of euros)	2012	2013	% change
Sales as of 31 March	41 809	43 033	+2,9%
Pharmaceutical Synthesis	25 454	26 677	+4,8%
Fine Speciality Chemicals	16 355	16 356	0,0%

The figures presented above do not include those for SBS, the sale of which was finalized on March 20, 2013. As a reminder, SBS was presented on a specific line "Net Result on discontinued operation" as of 31 December, 2012.

Consolidated net sales for the PCAS Group are up 2.9% in the first quarter of 2013 compared to the same period for the previous year.

Pharmaceutical Synthesis

Pharmaceutical Synthesis activities are continuing to develop in 2013, up 4.8% compared to 2012.

Fine Specialty Chemicals

Fine Specialty Chemicals net sales are stable overall in the first quarter of 2013, with satisfactory growths in Performance Chemicals activities.

In accordance with the wishes of the Board of Directors, the Group's General Management is focused on improving profitability.

Finally, on April 11, 2013 the Boards of Directors of PCAS and Dynaction approved the planned merger, with PCAS absorbing Dynaction. In line with the Group's development strategy, this merger will simplify the structures of the Dynaction-PCAS Group, achieve cost savings, and ensure better liquidity for PCAS's share. The operation is set to be finalized by the end of the first half of the year.

Next meeting: Shareholder's Meeting PCAS – Dynaction merger June 26, 2013, 10.45 a.m. in Longjumeau

About PCAS :

Founded in 1962, PCAS is an international fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability. PCAS also develops ranges of proprietary products based on intellectual property.